1. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update;American Society of Addiction Medicine;J. Addict. Med.,2020
2. Common themes in early state policy responses to substance use disorder treatment during COVID-19;Andraka-Christou;Am. J. Drug Alcohol Abus.,2021
3. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices;Andraka-Christou;Int. J. Drug Policy,2018
4. Andraka-Christou, B., Golan, O.K., Totaram, R., Ohama, M., Saloner, B., Gordon, A.J., Stein, B.D. , Unpublished results. Prior Authorization Restrictions on Medications for Opioid Use Disorder: Trends in State Laws from 2005–2019.
5. Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws;Andraka-Christou;J. Addict. Med.,2022